15-year accounting and finance career spans
several sectors including life sciences and underscores financial
leadership abilities
WEXFORD,
Pa., May 17, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the
"Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced today the appointment of
Brian Cogley, MBA, to the position
of Chief Financial Officer (CFO) effective immediately. Mr. Cogley
brings 15 years of accounting and finance experience to Coeptis,
having previously held positions of increasing authority at two
"Big 4" accounting firms and served on the management teams of
multiple companies in diverse industries. He succeeds Christine Sheehy, who will remain with Coeptis
in a senior finance capacity and as Vice President of Compliance
and Corporate Secretary.
As CFO, Mr. Cogley will be responsible for leading Coeptis'
financial and capital markets activities as the Company targets
multiple anticipated growth drivers resulting from the advancement
of its SNAP-CAR and GEAR™ programs and other opportunities. Mr.
Cogley joins Coeptis' leadership team alongside Dave Mehalick, Chairman, President and Chief
Executive Officer, and Dan Yerace,
Director and Vice President of Operations.
"We are excited to add Brian to the Coeptis Therapeutics team.
Hiring an individual of his capabilities reflects our commitment to
bringing in talented individuals with strong track records to our
company," stated Dave Mehalick,
President and CEO of Coeptis. "Brian's extensive and diverse
experience advising a range of public and private companies in a
variety of industries, including biotechnology and pharmaceuticals,
will be instrumental to the growth of Coeptis as we continue to
integrate and advance the SNAP-CAR and GEAR programs and as we
analyze current and future growth opportunities. On behalf of our
Coeptis, I am pleased to welcome Brian and look forward to working
with him."
An accountant by training, Mr. Cogley arrives at Coeptis with a
15-year career in corporate finance and accounting during which he
advised and led the financial operations for companies spanning
multiple industries including life sciences, pharmaceuticals,
financial services, and manufacturing. Most recently, Brian was a
Senior Manager, Accounting Advisory at CFGI, LLC where he served
pharmaceutical and financial services clients in technical
accounting implementations and execution, interim Controller roles,
interim SEC Reporting Manager roles, segment reporting and
carve-out engagements.
Prior to joining CFGI, Mr. Cogley held the position of Vice
President of Finance & Accounting at NexTier Bank where he was
a member of the Company's senior management team and led its
accounting and finance operations, including the general ledger,
financial planning and analysis, internal and external financial
reporting, and human resources. Prior to NexTier, Mr. Cogley held
the position of Global Cash Manager for Calgon Carbon Corporation,
where he was responsible for all daily cash decisions across the
global enterprise. Before joining Calgon Carbon, Mr. Cogley was a
Financial Analyst at TriState Capital Bank where he was responsible
for building its Sarbanes-Oxley control environment, SEC/regulatory
reporting and new system implementation, while also working on
various process improvement projects.
Mr. Cogley began his career at KPMG, LLP, providing audit and
assurance services to a variety of clients in the financial
services industry. Mr. Cogley earned a B.A. with a concentration in
accounting and a Master of Business Administration with a
concentration in finance from Duquesne
University.
"I am delighted to join the team at Coeptis Therapeutics,
especially at such an exciting time for the Company as it works to
advance its diverse pipeline of cell and gene therapies while at
the same time exploring expansion opportunities," stated Mr.
Cogley. "I look forward to working with Dave and the rest of the
management team, utilizing my financial expertise to help Coeptis
achieve its growth potential and generate value for both patients
and shareholders."
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and intellectual property and
knowhow related to the GEAR™ cell therapy and companion diagnostic
platforms, which Coeptis is developing with VyGen-Bio and
leading medical researchers at the Karolinska Institutet.
Coeptis' business model is designed around maximizing the value of
its current product portfolio and rights through in-license
agreements, out-license agreements and co-development
relationships, as well as entering into strategic partnerships to
expand its product rights and offerings, specifically those
targeting cancer. The Company is headquartered in Wexford, PA.
For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Global Market; (2) the risk that currently explored expansion
opportunities, if consummated, disrupts current plans and
operations of Company; (3) the inability to recognize the
anticipated benefits of the recently closed business combination,
which may be affected by, among other things, competition, the
ability of the Company to grow and manage growth economically and
hire and retain key employees; (4) the risks that the Company's
products in development or those targeted to enter the clinical
trial phase fail clinical trials or are not approved by the U.S.
Food and Drug Administration or other applicable regulatory
authorities; (5) costs related to our ongoing asset development
plans and our focus on business expansion opportunities; (6)
changes in applicable laws or regulations; (7) the possibility that
the Company may be adversely affected by other economic, business,
and/or competitive factors; and (8) the impact of the global
COVID-19 pandemic on any of the foregoing risks and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission (the "SEC"). The foregoing list
of factors is not exclusive. All forward-looking statements are
subject to significant uncertainties and risks including, but not
limited, to those risks contained or to be contained in reports and
other filings filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings made or
to be made with the SEC, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise
these forward-looking statements to reflect events or circumstances
that arise after the date hereof unless required by applicable
laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
dboateng@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original
content:https://www.prnewswire.com/news-releases/coeptis-therapeutics-appoints-brian-cogley-as-chief-financial-officer-301826573.html
SOURCE Coeptis Therapeutics